BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients

BriaCell Therapeutics Corp BCTX has provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast cancer patients.
These women were treated with BriaCell’s lead candidate, Bria-IMT, as monotherapy, and also in combination with checkpoint inhibitors, including Merck & Co Inc MRK Keytruda (pembrolizumab) and Incyte Corporation’s INCY retifanlimab.
12 months of average overall survival benefit was observed, including 13.4 months in patients with 2+ human leukocyte antigen (HLA) matches and 12.5 months in patients with Grade 1/2 tumors.
Top Responder achieved 21.4 months survival plus 100% resolution of ‘eye-bulging’ orbital tumor.
It compares to 7.2-9.8 months survival in historical comparison treatment trials.
Price Action: BCTX shares are up 104.1% at $6.50 during the premarket session on the last check Wednesday.